SCHEMBL25792010

SCHEMBL25792010

CCn1cc(Cl)nc1-c1ccc(C(=O)OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.47
ADORA2B P29275 2/20 0.47
DRD2 P14416 1/20 0.46
TBXA2R P21731 1/20 0.46
TLR8 Q9NR97 1/20 0.46
KDM4E B2RXH2 2/20 0.43
GAA P10253 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
RHEB Q15382 1/20 0.41
RAB9A P51151 1/20 0.41
DHODH Q02127 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25792046 0.86 TLR8 (0.48) ADORA2AADORA2BDRD2TBXA2RTLR8
SCHEMBL25297452 0.82 DGAT1 (0.57) ADORA2AADORA2BDRD2TBXA2RTLR8
SCHEMBL31497621 0.82 ADORA2A (0.52) ADORA2AADORA2BDRD2TBXA2RTLR8
SCHEMBL25181306 0.82 USP1 (0.45) ADORA2AADORA2BDRD2TBXA2RTLR8
SCHEMBL25792009 0.76 BRD4 (0.39)
SCHEMBL25792007 0.73 BRD4 (0.39) KDM4EGAAALDH1A1MAPTLMNA
SCHEMBL22122015 0.72 GABRA2 (0.41) DRD2TBXA2RTLR8KDM4EALDH1A1
SCHEMBL31255037 0.72 TLR8 (0.41) ADORA2AADORA2BDRD2TBXA2RTLR8
SCHEMBL22143292 0.71 ALDH1A1 (0.44) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL29225216 0.71 TLR8 (0.42) ADORA2AADORA2BDRD2TBXA2RTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, USP8, USP7 ADORA2A 4415/4885ADORA2B 4512/4885DRD2 4098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.